Clinical Edge Journal Scan

Increased variability in A1c and FPG is a risk factor for severe hypoglycemia


 

Key clinical point: In patients with type 2 diabetes (T2D), increased visit-to-visit variability in glycated hemoglobin (A1c) and fasting plasma glucose (FPG) was associated with a higher risk for severe hypoglycemia; however, FPG variability better predicted severe hypoglycemic events than A1c variability.

Major finding: Each standard deviation (SD) increase in the variability in A1c and FPG significantly increased the risk for hypoglycemia requiring any third-party assistance (adjusted hazard ratio [aHR] 1.10 and aHR 1.40, respectively; both P < .01) and hypoglycemia requiring medical assistance (aHR 1.11 and aHR 1.46, respectively; both P < .01). However, FPG variability better predicted severe hypoglycemic events than A1c variability (P < .01).

Study details: Findings are from a post hoc analysis of the ACCORD trial including patients with T2D and a high risk for cardiovascular disease, of which 10,052 and 10,068 patients were included in A1c and FPG variability analyses, respectively.

Disclosures: This study was partly supported by the National Science Foundation of China project. The authors declared no conflicts of interest.

Source: Long C et al. Association of long-term visit-to-visit variability of HbA1c and fasting glycemia with hypoglycemia in type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13:975468 (Aug 11). Doi: 10.3389/fendo.2022.975468

Recommended Reading

New AI tech could detect type 2 diabetes without a blood test
Type 2 Diabetes ICYMI
Lack of exercise linked to small heart, HFpEF
Type 2 Diabetes ICYMI
At EASD, docs to eye new tactics for type 2 diabetes
Type 2 Diabetes ICYMI
Canagliflozin reduces total CV burden in T2D patients with CKD
Type 2 Diabetes ICYMI
New-onset AF raises the risk for CVD, CKD, and mortality in T2D
Type 2 Diabetes ICYMI
Dapagliflozin prevents kidney function decline in T2D
Type 2 Diabetes ICYMI
Treatment advancement with iGlarLixi as effective as BI+RAI in real world in T2D
Type 2 Diabetes ICYMI
No effect of SGLT-2 inhibitors on cardiac autonomic neuropathy indices in T2D
Type 2 Diabetes ICYMI
Effect of DPP4 inhibitors on glycemic variability in T2D
Type 2 Diabetes ICYMI
SGLT2i vs DPP4i tied with reduced mortality and HF readmission risk in T2D patients with HF
Type 2 Diabetes ICYMI